Cargando…
Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C
Pathogenic protein-truncating variants of RAD51C, which plays an integral role in promoting DNA damage repair, increase the risk of breast and ovarian cancer. A large number of RAD51C missense variants of uncertain significance (VUS) have been identified, but the effects of the majority of these var...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390864/ https://www.ncbi.nlm.nih.gov/pubmed/37253112 http://dx.doi.org/10.1158/0008-5472.CAN-22-2319 |
_version_ | 1785082572024315904 |
---|---|
author | Hu, Chunling Nagaraj, Anil Belur Shimelis, Hermela Montalban, Gemma Lee, Kun Y. Huang, Huaizhi Lumby, Carolyn A. Na, Jie Susswein, Lisa R. Roberts, Maegan E. Marshall, Megan L. Hiraki, Susan LaDuca, Holly Chao, Elizabeth Yussuf, Amal Pesaran, Tina Neuhausen, Susan L. Haiman, Christopher A. Kraft, Peter Lindstrom, Sara Palmer, Julie R. Teras, Lauren R. Vachon, Celine M. Yao, Song Ong, Irene Nathanson, Katherine L. Weitzel, Jeffrey N. Boddicker, Nicholas Gnanaolivu, Rohan Polley, Eric C. Mer, Georges Cui, Gaofeng Karam, Rachid Richardson, Marcy E. Domchek, Susan M. Yadav, Siddhartha Hruska, Kathleen S. Dolinsky, Jill Weroha, S. John Hart, Steven N. Simard, Jacques Masson, Jean Yves Pang, Yuan-Ping Couch, Fergus J. |
author_facet | Hu, Chunling Nagaraj, Anil Belur Shimelis, Hermela Montalban, Gemma Lee, Kun Y. Huang, Huaizhi Lumby, Carolyn A. Na, Jie Susswein, Lisa R. Roberts, Maegan E. Marshall, Megan L. Hiraki, Susan LaDuca, Holly Chao, Elizabeth Yussuf, Amal Pesaran, Tina Neuhausen, Susan L. Haiman, Christopher A. Kraft, Peter Lindstrom, Sara Palmer, Julie R. Teras, Lauren R. Vachon, Celine M. Yao, Song Ong, Irene Nathanson, Katherine L. Weitzel, Jeffrey N. Boddicker, Nicholas Gnanaolivu, Rohan Polley, Eric C. Mer, Georges Cui, Gaofeng Karam, Rachid Richardson, Marcy E. Domchek, Susan M. Yadav, Siddhartha Hruska, Kathleen S. Dolinsky, Jill Weroha, S. John Hart, Steven N. Simard, Jacques Masson, Jean Yves Pang, Yuan-Ping Couch, Fergus J. |
author_sort | Hu, Chunling |
collection | PubMed |
description | Pathogenic protein-truncating variants of RAD51C, which plays an integral role in promoting DNA damage repair, increase the risk of breast and ovarian cancer. A large number of RAD51C missense variants of uncertain significance (VUS) have been identified, but the effects of the majority of these variants on RAD51C function and cancer predisposition have not been established. Here, analysis of 173 missense variants by a homology-directed repair (HDR) assay in reconstituted RAD51C(−/−) cells identified 30 nonfunctional (deleterious) variants, including 18 in a hotspot within the ATP-binding region. The deleterious variants conferred sensitivity to cisplatin and olaparib and disrupted formation of RAD51C/XRCC3 and RAD51B/RAD51C/RAD51D/XRCC2 complexes. Computational analysis indicated the deleterious variant effects were consistent with structural effects on ATP-binding to RAD51C. A subset of the variants displayed similar effects on RAD51C activity in reconstituted human RAD51C-depleted cancer cells. Case–control association studies of deleterious variants in women with breast and ovarian cancer and noncancer controls showed associations with moderate breast cancer risk [OR, 3.92; 95% confidence interval (95% CI), 2.18–7.59] and high ovarian cancer risk (OR, 14.8; 95% CI, 7.71–30.36), similar to protein-truncating variants. This functional data supports the clinical classification of inactivating RAD51C missense variants as pathogenic or likely pathogenic, which may improve the clinical management of variant carriers. SIGNIFICANCE: Functional analysis of the impact of a large number of missense variants on RAD51C function provides insight into RAD51C activity and information for classification of the cancer relevance of RAD51C variants. |
format | Online Article Text |
id | pubmed-10390864 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Association for Cancer Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-103908642023-08-02 Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C Hu, Chunling Nagaraj, Anil Belur Shimelis, Hermela Montalban, Gemma Lee, Kun Y. Huang, Huaizhi Lumby, Carolyn A. Na, Jie Susswein, Lisa R. Roberts, Maegan E. Marshall, Megan L. Hiraki, Susan LaDuca, Holly Chao, Elizabeth Yussuf, Amal Pesaran, Tina Neuhausen, Susan L. Haiman, Christopher A. Kraft, Peter Lindstrom, Sara Palmer, Julie R. Teras, Lauren R. Vachon, Celine M. Yao, Song Ong, Irene Nathanson, Katherine L. Weitzel, Jeffrey N. Boddicker, Nicholas Gnanaolivu, Rohan Polley, Eric C. Mer, Georges Cui, Gaofeng Karam, Rachid Richardson, Marcy E. Domchek, Susan M. Yadav, Siddhartha Hruska, Kathleen S. Dolinsky, Jill Weroha, S. John Hart, Steven N. Simard, Jacques Masson, Jean Yves Pang, Yuan-Ping Couch, Fergus J. Cancer Res Translational Cancer Biology Pathogenic protein-truncating variants of RAD51C, which plays an integral role in promoting DNA damage repair, increase the risk of breast and ovarian cancer. A large number of RAD51C missense variants of uncertain significance (VUS) have been identified, but the effects of the majority of these variants on RAD51C function and cancer predisposition have not been established. Here, analysis of 173 missense variants by a homology-directed repair (HDR) assay in reconstituted RAD51C(−/−) cells identified 30 nonfunctional (deleterious) variants, including 18 in a hotspot within the ATP-binding region. The deleterious variants conferred sensitivity to cisplatin and olaparib and disrupted formation of RAD51C/XRCC3 and RAD51B/RAD51C/RAD51D/XRCC2 complexes. Computational analysis indicated the deleterious variant effects were consistent with structural effects on ATP-binding to RAD51C. A subset of the variants displayed similar effects on RAD51C activity in reconstituted human RAD51C-depleted cancer cells. Case–control association studies of deleterious variants in women with breast and ovarian cancer and noncancer controls showed associations with moderate breast cancer risk [OR, 3.92; 95% confidence interval (95% CI), 2.18–7.59] and high ovarian cancer risk (OR, 14.8; 95% CI, 7.71–30.36), similar to protein-truncating variants. This functional data supports the clinical classification of inactivating RAD51C missense variants as pathogenic or likely pathogenic, which may improve the clinical management of variant carriers. SIGNIFICANCE: Functional analysis of the impact of a large number of missense variants on RAD51C function provides insight into RAD51C activity and information for classification of the cancer relevance of RAD51C variants. American Association for Cancer Research 2023-08-01 2023-05-30 /pmc/articles/PMC10390864/ /pubmed/37253112 http://dx.doi.org/10.1158/0008-5472.CAN-22-2319 Text en ©2023 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. |
spellingShingle | Translational Cancer Biology Hu, Chunling Nagaraj, Anil Belur Shimelis, Hermela Montalban, Gemma Lee, Kun Y. Huang, Huaizhi Lumby, Carolyn A. Na, Jie Susswein, Lisa R. Roberts, Maegan E. Marshall, Megan L. Hiraki, Susan LaDuca, Holly Chao, Elizabeth Yussuf, Amal Pesaran, Tina Neuhausen, Susan L. Haiman, Christopher A. Kraft, Peter Lindstrom, Sara Palmer, Julie R. Teras, Lauren R. Vachon, Celine M. Yao, Song Ong, Irene Nathanson, Katherine L. Weitzel, Jeffrey N. Boddicker, Nicholas Gnanaolivu, Rohan Polley, Eric C. Mer, Georges Cui, Gaofeng Karam, Rachid Richardson, Marcy E. Domchek, Susan M. Yadav, Siddhartha Hruska, Kathleen S. Dolinsky, Jill Weroha, S. John Hart, Steven N. Simard, Jacques Masson, Jean Yves Pang, Yuan-Ping Couch, Fergus J. Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C |
title | Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C |
title_full | Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C |
title_fullStr | Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C |
title_full_unstemmed | Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C |
title_short | Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C |
title_sort | functional and clinical characterization of variants of uncertain significance identifies a hotspot for inactivating missense variants in rad51c |
topic | Translational Cancer Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390864/ https://www.ncbi.nlm.nih.gov/pubmed/37253112 http://dx.doi.org/10.1158/0008-5472.CAN-22-2319 |
work_keys_str_mv | AT huchunling functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT nagarajanilbelur functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT shimelishermela functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT montalbangemma functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT leekuny functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT huanghuaizhi functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT lumbycarolyna functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT najie functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT sussweinlisar functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT robertsmaegane functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT marshallmeganl functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT hirakisusan functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT laducaholly functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT chaoelizabeth functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT yussufamal functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT pesarantina functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT neuhausensusanl functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT haimanchristophera functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT kraftpeter functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT lindstromsara functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT palmerjulier functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT teraslaurenr functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT vachoncelinem functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT yaosong functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT ongirene functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT nathansonkatherinel functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT weitzeljeffreyn functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT boddickernicholas functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT gnanaolivurohan functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT polleyericc functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT mergeorges functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT cuigaofeng functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT karamrachid functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT richardsonmarcye functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT domcheksusanm functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT yadavsiddhartha functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT hruskakathleens functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT dolinskyjill functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT werohasjohn functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT hartstevenn functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT simardjacques functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT massonjeanyves functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT pangyuanping functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c AT couchfergusj functionalandclinicalcharacterizationofvariantsofuncertainsignificanceidentifiesahotspotforinactivatingmissensevariantsinrad51c |